Overexpression of HER2/neu as a Prognostic Value in Iranian Women With Early Stage Breast Cancer; A Single Institute Study | Zendy

Hanifeh MirtavoosMahyari | Zendy; Adnan Khosravi | Zendy; Zeinab Mirtavoos Mahyari | Zendy; Zahra Esfahani Monfared | Zendy; Negin Khosravi | Zendy

Open Access

Overexpression of HER2/neu as a Prognostic Value in Iranian Women With Early Stage Breast Cancer; A Single Institute Study

Author(s) -

Hanifeh MirtavoosMahyari,

Adnan Khosravi,

Zeinab Mirtavoos Mahyari,

Zahra Esfahani Monfared,

Negin Khosravi

Publication year - 2014

Publication title -

iranian red crescent medical journal

Language(s) - English

Resource type - Journals

eISSN - 2074-1812

pISSN - 2074-1804

DOI - 10.5812/ircmj.16005

Subject(s) - medicine , breast cancer , oncology , stage (stratigraphy) , immunohistochemistry , pathological , chemotherapy , hormone receptor , trastuzumab , adjuvant , adjuvant chemotherapy , her2/neu , human epidermal growth factor receptor 2 , multivariate analysis , cancer , fluorescence in situ hybridization , gene , paleontology , biochemistry , chemistry , chromosome , biology

Patients with early stage breast cancer with same treatment strategy can have markedly different outcomes. Human epidermal growth factor receptor 2 (HER2/nue) gene amplification or the subsequent overexpression of protein has been proved to be associated with patient's outcome and response to anthracyclins-based regimens.This study assessed prognostic value of HER2/nue marker in patients with early stage breast cancer who received adjuvant chemotherapy with anthracyclins-based regimens.Fifty tissue samples from patients with primary breast cancer of moderate risk receiving sequential adjuvant chemotherapy with anthracyclins-based regimens were assessed to evaluate HER2/nue gene status (quantified by Immunohistochemistry and fluorescence in situ hybridization) retrospectively. Besides, correlation of HER2/neu with patients' characteristics and outcome was studied.HER2/neu amplification was identified in 19 (38%) of 50 patients. No significant difference regarding HER2/neu status was seen in clinic pathological characteristics of patients. Although Progression Free Survival (PFS) was shorter in HER2 overexpressed group, but uni/multivariate analysis adjusted for HER2 overexpression, nodal involvement, hormone receptor status, age and tumor size revealed no significant predictive and/or prognostic value for HER2 regarding PFS.This study on a limited number of patients treated with adjutant anthracyclins-based regimens, revealed that HER2/neu is not a unique strong predictor for outcome, thus according to combination of HER2/neu status and other clinical factors, it is necessary to distinguish patients at high risk of recurrence.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research